Gilead Sciences Eulerpool Ziņas

Gilead Sciences Akciju Ziņas

Gilead Sciences tiek uzmanīgi vēroti no žurnālistu un investoru puses visā pasaulē. Jaunākās Gilead Sciences ziņas mēs apkopojam šeit.

• 22. jūlijs ·

  SeekingAlpha
  Lyell: 'Hold' Rating Based On Phase 3 LYL314 LBCL Treatment Program Advancement
• 19. jūlijs ·

  SeekingAlpha
  Our Top 10 High Growth Dividend Stocks - July 2025
• 19. jūlijs ·

  Yahoo
  Why Gilead Sciences (GILD) Appeals to Income Investors in the Pharma Sector
• 18. jūlijs ·

  Yahoo
  Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock?
• 17. jūlijs ·

  Yahoo
  GSK’s Linerixibat Poised to Address Substantial Unmet Need for the Treatment of Pruritus Associated with Primary Biliary Cholangitis, According to Spherix Global Insights
• 17. jūlijs ·

  Yahoo
  Human Immunodeficiency Virus (HIV) 7MM Drug Forecast and Analysis Report 2023-2033 | Market to Reach $32.1 Billion - Gilead Sciences to Remain the Leading Player
• 17. jūlijs ·

  Yahoo
  Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
• 16. jūlijs ·

  SeekingAlpha
  Why Merck Is A Better Dividend Stock Than Gilead Sciences
• 16. jūlijs ·

  Yahoo
  Q1 Earnings Roundup: Gilead Sciences (NASDAQ:GILD) And The Rest Of The Therapeutics Segment
• 16. jūlijs ·

  SeekingAlpha
  Amgen: Biosimilars And Rare Disease Pipeline Crucial To Overcome Patent Cliff Concerns